What is a stock summary page? Click here for an overview.
Business Description
Abbott Laboratories (Pakistan) Ltd
ISIN : PK0025701019
Compare
Compare
Traded in other countries / regions
ABOT.Pakistan IPO Date
1982-06-14Description
Abbott Laboratories (Pakistan) Ltd manufactures, imports, and markets research-based pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. Its operating segments are Pharmaceutical, Nutritional, Diagnostics, and Others. It generates maximum revenue from the Pharmaceutical segment. Geographically, it derives the majority of its revenue from Pakistan and has a presence in Afghanistan, Sri Lanka, Bangladesh, and Switzerland. Its Brands include Duphaston, Brufen, Surbex Z, Arinac, Glucerna, Pediasure, and Ensure.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 118.37 | |||||
| Equity-to-Asset | 0.63 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Interest Coverage | 722.61 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 7.31 | |||||
| Beneish M-Score | -1.92 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 17 | |||||
| 3-Year EBITDA Growth Rate | 3.9 | |||||
| 3-Year EPS without NRI Growth Rate | -4.3 | |||||
| 3-Year FCF Growth Rate | -34.1 | |||||
| 3-Year Book Growth Rate | 11 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.72 | |||||
| 9-Day RSI | 45.64 | |||||
| 14-Day RSI | 44.32 | |||||
| 3-1 Month Momentum % | -9.74 | |||||
| 6-1 Month Momentum % | 32.13 | |||||
| 12-1 Month Momentum % | 93.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.99 | |||||
| Quick Ratio | 1.03 | |||||
| Cash Ratio | 0.53 | |||||
| Days Inventory | 94.93 | |||||
| Days Sales Outstanding | 12.56 | |||||
| Days Payable | 58.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward Dividend Yield % | 0.97 | |||||
| Shareholder Yield % | 0.1 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 28.95 | |||||
| Operating Margin % | 12.44 | |||||
| Net Margin % | 7.68 | |||||
| FCF Margin % | 2.42 | |||||
| ROE % | 24.98 | |||||
| ROA % | 14.26 | |||||
| ROIC % | 20.2 | |||||
| 3-Year ROIIC % | -7.6 | |||||
| ROC (Joel Greenblatt) % | 55.3 | |||||
| ROCE % | 40.11 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.83 | |||||
| PE Ratio without NRI | 19.89 | |||||
| Shiller PE Ratio | 24.15 | |||||
| Price-to-Owner-Earnings | 63.62 | |||||
| PEG Ratio | 1.81 | |||||
| PS Ratio | 1.52 | |||||
| PB Ratio | 4.38 | |||||
| Price-to-Tangible-Book | 4.38 | |||||
| Price-to-Free-Cash-Flow | 62.82 | |||||
| Price-to-Operating-Cash-Flow | 22.21 | |||||
| EV-to-EBIT | 10.69 | |||||
| EV-to-EBITDA | 8.95 | |||||
| EV-to-Revenue | 1.43 | |||||
| EV-to-FCF | 57.15 | |||||
| Price-to-GF-Value | 1.27 | |||||
| Price-to-Projected-FCF | 2.45 | |||||
| Price-to-Median-PS-Value | 0.77 | |||||
| Price-to-Graham-Number | 1.97 | |||||
| Price-to-Net-Current-Asset-Value | 11.12 | |||||
| Earnings Yield (Greenblatt) % | 9.36 | |||||
| FCF Yield % | 1.59 | |||||
| Forward Rate of Return (Yacktman) % | 5.6 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Abbott Laboratories (Pakistan) Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₨) | 68,177.197 | ||
| EPS (TTM) (₨) | 53.46 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.48 | ||
| 3-Year Sortino Ratio | 0.8 | ||
| Volatility % | 39.41 | ||
| 14-Day RSI | 44.32 | ||
| 14-Day ATR (₨) | 37.680983 | ||
| 20-Day SMA (₨) | 1068.5845 | ||
| 12-1 Month Momentum % | 93.98 | ||
| 52-Week Range (₨) | 518.02 - 1310 | ||
| Shares Outstanding (Mil) | 97.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abbott Laboratories (Pakistan) Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Abbott Laboratories (Pakistan) Ltd Stock Events
| Event | Date | Price (₨) | ||
|---|---|---|---|---|
| No Event Data | ||||
Abbott Laboratories (Pakistan) Ltd Frequently Asked Questions
What is Abbott Laboratories (Pakistan) Ltd(KAR:ABOT)'s stock price today?
The current price of KAR:ABOT is ₨1060.18. The 52 week high of KAR:ABOT is ₨1310.00 and 52 week low is ₨518.02.
When is next earnings date of Abbott Laboratories (Pakistan) Ltd(KAR:ABOT)?
The next earnings date of Abbott Laboratories (Pakistan) Ltd(KAR:ABOT) is .
Does Abbott Laboratories (Pakistan) Ltd(KAR:ABOT) pay dividends? If so, how much?
Abbott Laboratories (Pakistan) Ltd(KAR:ABOT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers